Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling.

Journal: Seminars in cancer biology
Published Date:

Abstract

The complexity of diagnostic (surgical) pathology has increased substantially over the last decades with respect to histomorphological and molecular profiling. Pathology has steadily expanded its role in tumor diagnostics and beyond from disease entity identification via prognosis estimation to precision therapy prediction. It is therefore not surprising that pathology is among the disciplines in medicine with high expectations in the application of artificial intelligence (AI) or machine learning approaches given their capabilities to analyze complex data in a quantitative and standardized manner to further enhance scope and precision of diagnostics. While an obvious application is the analysis of histological images, recent applications for the analysis of molecular profiling data from different sources and clinical data support the notion that AI will enhance both histopathology and molecular pathology in the future. At the same time, current literature should not be misunderstood in a way that pathologists will likely be replaced by AI applications in the foreseeable future. Although AI will transform pathology in the coming years, recent studies reporting AI algorithms to diagnose cancer or predict certain molecular properties deal with relatively simple diagnostic problems that fall short of the diagnostic complexity pathologists face in clinical routine. Here, we review the pertinent literature of AI methods and their applications to pathology, and put the current achievements and what can be expected in the future in the context of the requirements for research and routine diagnostics.

Authors

  • Albrecht Stenzinger
    From the Division of Radiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany (P.S., J.P.R., P.K., H.P.S., D.B.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (S.K., K.H.M.H.); Department of Urology, University of Heidelberg Medical Center, Heidelberg, Germany (J.P.R., M.H.); Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany (M.W.); Department of Neuroradiology, University of Heidelberg Medical Center, Heidelberg, Germany (P.K.); Junior Group Medical Imaging and Radiology-Cancer Prevention, German Cancer Research Center (DKFZ), Heidelberg, Germany (S.B.); Division of Medical Physics, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.A.K.); Institute of Pathology, University of Heidelberg Medical Center, Heidelberg, Germany (A.S.); and German Cancer Consortium (DKTK), Heidelberg, Germany (H.P.S., K.H.M.H., D.B.).
  • Maximilian Alber
    Berlin Big Data Center, Berlin Institute of Technology, Berlin, Germany.
  • Michael Allgäuer
    Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, Heidelberg, 69120, Germany.
  • Philipp Jurmeister
    Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 10117 Berlin, Germany.
  • Michael Bockmayr
    Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 10117 Berlin, Germany.
  • Jan Budczies
    Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, Heidelberg, 69120, Germany; German Cancer Consortium (DKTK), Partner Site Heidelberg, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Jochen Lennerz
    Department of Pathology, Center for Integrated Diagnostics, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
  • Johannes Eschrich
    Department of Hepatology & Gastroenterology, Charité University Medical Center, Berlin, Germany.
  • Daniel Kazdal
    Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, Heidelberg, 69120, Germany; German Center for Lung Research (DZL), Partner Site Heidelberg, Heidelberg, Germany.
  • Peter Schirmacher
    Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; Liver Cancer Center Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
  • Alex H Wagner
    McDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Frank Tacke
    Hepatology and Gastroenterology, Charité University Medicine, Berlin, Germany.
  • David Capper
    German Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), 69210 Heidelberg, Germany. frederick.klauschen@charite.de david.capper@charite.de.
  • Klaus-Robert Müller
    Berlin Institute for the Foundations of Learning and Data (BIFOLD), Berlin, Deutschland.
  • Frederick Klauschen
    Pathologisches Institut, Ludwig-Maximilians-Universität München, Thalkirchner Str. 36, 80337, München, Deutschland. f.klauschen@lmu.de.